Study S000736

A Phase Ib, Randomized, Open-Label, Multi-Center, 4-Week Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITCA 650 in Subjects With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01798264
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 44
Start: 2009-02
Primary completion: 2009-05
Lead sponsor: Intarcia Therapeutics
Conditions: Type 2 Diabetes
Interventions: DRUG:ITCA 650 (exenatide in DUROS)
Results posted: TRUE

Registered primary outcomes

Number of Subjects With Study Drug-Related Adverse Events [4 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014538	A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes. Henry RR, Clinical therapeutics	2013	Randomized trial	PMID 23578605 DOI	cites ClinicalTrials.gov:NCT01798264; registry reference DERIVED:23578605